Shares of St. Jude Medical Inc. (NYSE:STJ) reached a new 52-week high during trading on Monday . The company traded as high as $83.80 and last traded at $83.40, with a volume of 758,039 shares trading hands. The stock had previously closed at $83.04.

Several analysts have recently weighed in on the stock. Zacks Investment Research cut shares of St. Jude Medical from a “hold” rating to a “sell” rating in a research note on Tuesday, April 12th. Bank of America Corp. reissued a “buy” rating and issued a $66.00 price target on shares of St. Jude Medical in a research note on Friday, April 15th. Barclays PLC cut shares of St. Jude Medical from an “overweight” rating to an “equal weight” rating and increased their price target for the company from $74.00 to $80.00 in a research note on Wednesday, May 11th. Canaccord Genuity set a $85.00 price target on shares of St. Jude Medical and gave the company a “hold” rating in a research note on Wednesday, July 20th. Finally, Needham & Company LLC cut shares of St. Jude Medical from a “buy” rating to a “hold” rating in a research note on Friday, April 29th. Twenty-two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. St. Jude Medical currently has a consensus rating of “Hold” and a consensus price target of $75.93.

The stock has a 50-day moving average of $79.60 and a 200 day moving average of $66.36. The firm has a market cap of $24.08 billion and a P/E ratio of 36.31.

St. Jude Medical (NYSE:STJ) last announced its earnings results on Wednesday, July 20th. The medical technology company reported $1.06 EPS for the quarter, hitting the consensus estimate of $1.06. The firm earned $1.56 billion during the quarter, compared to analyst estimates of $1.55 billion. The business’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.07 earnings per share. On average, analysts anticipate that St. Jude Medical Inc. will post $4.06 earnings per share for the current fiscal year.

Other hedge funds and institutional investors have recently made changes to their positions in the company. BlackRock Advisors LLC boosted its position in shares of St. Jude Medical by 0.7% in the fourth quarter. BlackRock Advisors LLC now owns 2,322,921 shares of the medical technology company’s stock valued at $143,486,000 after buying an additional 15,602 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in St. Jude Medical by 32.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 823,890 shares of the medical technology company’s stock worth $50,894,000 after buying an additional 199,858 shares during the period. BNP Paribas Arbitrage SA raised its stake in St. Jude Medical by 2.7% in the fourth quarter. BNP Paribas Arbitrage SA now owns 35,027 shares of the medical technology company’s stock worth $2,164,000 after buying an additional 911 shares during the period. Dorsey & Whitney Trust CO LLC raised its stake in St. Jude Medical by 6.9% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 54,103 shares of the medical technology company’s stock worth $3,343,000 after buying an additional 3,484 shares during the period. Finally, I.G. Investment Management LTD. raised its stake in St. Jude Medical by 29.7% in the fourth quarter. I.G. Investment Management LTD. now owns 228,600 shares of the medical technology company’s stock worth $14,121,000 after buying an additional 52,300 shares during the period.

St. Jude Medical, Inc is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.